TXG Maintained by UBS -- Price Target Raised to $68

gurufocus.com · 2026-09-09

On October 03, 2023, 10x Genomics (TXG) received a neutral rating from UBS, with analyst Dan Leonard announcing a substantial price target increase. The adjuste

TickrTrends take: UBS has raised its price target for TXG to 68, which represents a shift in analyst positioning even as the firm maintained its rating stance. For valuation-focused investors, this development is relevant given that TickrTrends' current assessment for TXG remains awaiting full valuation in the Healthcare sector, meaning a comprehensive valuation picture has not yet solidified. The raised price target from a major analyst provides a data point that could inform the eventual full valuation framework as more information accumulates.

Read the full story at gurufocus.com →